A menstruating 44-year-old has two axillary macrometastases after resection of a hormone-receptor-positive, HER2-negative tumour. A commercially

Question

A menstruating 44-year-old has two axillary macrometastases after resection of a hormone-receptor-positive, HER2-negative tumour. A commercially obtained 21-gene expression result is 14, and she requests endocrine therapy alone. How should current NICE HTG719 affect use of this result?

Accepted Answer

Do not use the score to omit chemotherapy in this node-positive premenopausal patient

Answer

Repeat the assay with Prosigna and use its result to determine chemotherapy benefit

Answer

Omit chemotherapy by applying the postmenopausal recurrence-score interpretation to this patient

Answer

Apply the node-negative evidence-generation recommendation to the low recurrence score

Answer

Use MammaPrint as the profiling test for node-positive premenopausal disease

Breast Cancer — SCE Medical Oncology MCQ

A menstruating 44-year-old has two axillary macrometastases after resection of a hormone-receptor-positive, HER2-negative tumour. A commercially obtained 21-gene expression result is 14, and she requests endocrine therapy alone. How should current NICE HTG719 affect use of this result?